logo
Huge Study Shows Where Gout Comes From – It's Not What We Thought

Huge Study Shows Where Gout Comes From – It's Not What We Thought

Yahoo12-02-2025

Gout is often associated with drinking too much or not eating healthily enough, but research suggests genetics play more of a factor in developing the arthritic condition than previously thought.
A recent study, carried out by an international team of scientists, looked at genetic data collected from 2.6 million people across 13 different cohorts of DNA data. That number included 120,295 people with "prevalent gout".
By comparing the genetic codes of the people with gout against the people without, the team found 377 specific DNA regions where there were variations specific to having the condition – 149 of which hadn't been previously linked to gout.
While lifestyle and environmental factors are certainly still in play, the findings suggest genetics play a major role in determining whether or not someone gets gout – and the researchers think there may be more undiscovered genetic links still to be found, too.
"Gout is a chronic disease with a genetic basis and is not the fault of the sufferer – the myth that gout is caused by lifestyle or diet needs to be busted," said epidemiologist Tony Merriman from the University of Otago in New Zealand, when the study was published last year.
Gout takes hold when there are high levels of uric acid in the blood, which then form sharp crystal needles in the joints. When the body's immune system starts to attack those crystals, it leads to significant pain and discomfort.
Genetics is important in every stage of that process, the researchers suggest. Particularly, it affects the likelihood of the body's immune system attacking the crystals, and in the way uric acid is transported around the body.
Gout can come and go, but there are treatments available – and the authors behind the study think misconceptions can put people off getting those treatments. That's a real problem with cases of the condition rising and rising.
"This widespread myth causes shame in people with gout, making some people more likely to suffer in silence and not go and see the doctor to get a preventive drug that lowers urate in the blood and will prevent their pain," said Merriman.
On top of giving us a better understanding of the causes of gout, the study gives scientists more options to explore when it comes to treatments, particularly in terms of managing the body's immune response to the build up of uric acid. In fact, existing drugs could be repurposed for this job.
There are some limitations to the study: the majority of the data was from people of European ancestry, and some records relied on the self-reporting of gout rather than a clinical diagnosis. Nevertheless, it gives us a much better sense of a health problem that's been afflicting people for centuries.
"We hope that, in time, better and more accessible treatments will become available with the new targets we identified," said Merriman. "Gout deserves more health spend resource and greater prioritization in the health system."
The research has been published in Nature Genetics.
An earlier version of this article was published in November 2024.
Identifying Chemicals in Our Environment Could Help Medicines Work Better
How Well Is Your Gut Working? There's a Grossly Simple Way to Check.
A Shocking Number Still Don't Know The Risk of Taking Aspirin Each Day

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

No drug price pledges in talks with US government, Pfizer CEO says
No drug price pledges in talks with US government, Pfizer CEO says

Yahoo

timean hour ago

  • Yahoo

No drug price pledges in talks with US government, Pfizer CEO says

STORY: Pfizer CEO Albert Bourla said Monday that he and other drug companies met with the Trump administration to discuss lowering U.S. drug prices but no commitments have been made. He made the comments at a Goldman Sachs healthcare conference. Last month President Trump issued an executive order directing drugmakers to lower the prices of their medicines to align with what other countries pay. According to the order, the administration was to set "Most Favored Nation" price targets within 30 days. The Department of Health and Human Services has said it expects drugmakers in the U.S. to set prices for their products at the lowest price paid by other high-income countries. Bourla said he didn't know what the companies would hear in 30 days and added the meetings with the administration so far were cordial but (quote) "not digging into the substance." It is unclear what mechanism the U.S. government will use to lower drug prices - analysts and legal experts have said the policy will be difficult to implement. Bourla said he is hopeful that, given U.S. pressure on European countries to pay more, prices there could increase. He said that if the U.S. resorts to price controls, Pfizer could consider not making drugs available for government reimbursement in some countries if prices don't increase there. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Newel Health obtains EU MDR for blood pressure management platform
Newel Health obtains EU MDR for blood pressure management platform

Yahoo

time5 hours ago

  • Yahoo

Newel Health obtains EU MDR for blood pressure management platform

Amid the growing prevalence of hypertension in the EU, Italian health tech Newel Health has secured a CE mark for its Amicomed platform under the EU's Medical Device Regulation (EU MDR), enabling it to support the management of high blood pressure. Compatible with blood pressure monitors including Apple Health and Google Fit, the smartphone app-based platform captures structured blood pressure data and translates it into 'clinically meaningful' insights, Newel Health stated, and offers personalised feedback towards high blood pressure management based on real-world data. The platform's features include medication reminders to improve adherence, and personalised lifestyle and dietary recommendations based on a user's clinical profile. The capabilities are supported by Amicomed's architecture. Developed by Newel Health, the proprietary platform uses artificial intelligence (AI)-based predictive models to improve behavioural segmentation, sustain engagement, and adapt interventions based on an individual's profile. A 2023 report by GlobalData forecasts that AI platforms in healthcare will reach a valuation of $18.8bn by 2027. Newel Health CEO, Ervin Ukaj commented: "We designed Amicomed to offer a digital therapy that fits into people's everyday lives, supporting them, day by day, in managing hypertension. "The MDR certification confirms the strength of our platform and the reliability of our regulatory approach.' Ukaj added that Newel intends to pursue 'scalable growth' by seeking further partnerships with public and private healthcare stakeholders. Systemic hypertension is a key risk factor for chronic disease burden, and a known precursor for cardiovascular diseases (CVDs) including atherosclerotic cardiovascular disease, with research indicating that hypertension in the EU is on the rise. A European Commission (EC) survey from 2019 found that 22% of individuals aged 15 and above reported having received a high blood pressure diagnosis from a medical professional, while a 2023 report by the World Health Organization (WHO) estimates that the number of adults with hypertension in the European region and the Americas rose from 302 million in 1990 to 427 million in 2019 – reflecting a 41% rise. All medical device manufacturers marketing products in the EU must fall in line with the dictates of the EU MDR regulation by 2028. Introduced in 2017 and coming into its 'first phase' of effect in 2021, the EU MDR is promulgated as a means to centralise competencies at the EU level. While well-intentioned, some observers have deemed the regulation's roll out a 'disaster', with concerns around a perceived lack of clarity, and the regulation's overall scope and complexity – factors that have proven particularly challenging for companies with existing device on the European market. "Newel Health obtains EU MDR for blood pressure management platform" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

TeleTracking and Palantir partner for operational decision-making in healthcare
TeleTracking and Palantir partner for operational decision-making in healthcare

Yahoo

time5 hours ago

  • Yahoo

TeleTracking and Palantir partner for operational decision-making in healthcare

TeleTracking Technologies has collaborated with Palantir Technologies to enhance operational decision-making in healthcare. This strategic partnership is set to offer long-term value to healthcare providers worldwide by integrating TeleTracking's Operations IQ platform with the analytics and Palantir's AI-driven operating system, Palantir Foundry and AIP. Combining the operational workflow expertise of TeleTracking with the decision intelligence capabilities of Palantir, the partnership will enable caregivers to integrate and analyse various data types. This includes clinical, operational, financial, workforce, and third-party information. The goal is to use predictive forecasting and demand modelling to manage capacity, staffing, and resources more efficiently. The partnership will facilitate transparency and almost instantaneous awareness of circumstances across different areas or systems, leading to the optimisation of crucial resources throughout the entire organisation. It will also enhance the movement of patients through operational command centres. The distinctive operational information provided by TeleTracking, together with the AI-native platform from Palantir, seeks to automate operational procedures, lessening the load on staff and caregivers while also enhancing patient care and financial results. Palantir CEO Alex Karp said: 'This partnership with TeleTracking represents the AI revolution in healthcare we are in the midst of, where we continue to move closer to a world where all hospitals and health systems are embracing, implementing, and operating with an AI-powered approach, helping to streamline operations allowing for increased focus on providing the best level of care.' Health systems, regardless of their sizes, benefit from improved operational coordination, multi-hospital system management, and strategic planning powered by data. The partnership is designed to tailor their response capability to changing patient requirements and help to achieve cost efficiency. Earlier this year, TeleTracking announced a five-year collaboration with European applied AI company Faculty. This partnership aims to bring AI-powered automation and predictive capabilities to health systems and hospitals. "TeleTracking and Palantir partner for operational decision-making in healthcare" was originally created and published by Hospital Management, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store